

# **AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA373)**

## **NICE GUIDANCE ISSUED DECEMBER 2015**

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

### **Final Appraisal Recommendation**

**Advice No: 0514 – February 2014**

**Tocilizumab (RoActemra<sup>®</sup>) 20 mg/ml (4 ml, 10 ml and 20 ml vials) concentrate for solution for infusion**

**Limited submission by Roche Products Ltd**

### **Recommendation of AWMSG**

**Tocilizumab (RoActemra<sup>®</sup>) is recommended as an option for use within NHS Wales in combination with methotrexate (MTX) for the treatment of juvenile idiopathic polyarthritis (rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. Tocilizumab can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.**

**This recommendation applies only in circumstances where the approved Patient Access Scheme is utilised.**

#### **Additional note:**

- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1851), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

This recommendation has been ratified by the Minister for Health and Social Services and will be considered for review in three years.

Marketing authorisation holder on first issue:	Roche Products Ltd
Date of first issue	February 2014
Last reviewed	February 2017

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 0514:  
Tocilizumab (RoActemra<sup>®</sup>) 20 mg/ml concentrate for solution for infusion. February 2014.